CN1493315A - Medicine for treating chronic hepatitis B - Google Patents

Abstract

A Chinese medicine for treating chronic viral hepatitis B is prepared from 40 Chinese-medicinal materials including astragalus root, Chinese angelica root, red sage root, ground bottle, etc. Its advantages are stable curative effect low toxic by-effect and low cost.

Description

The medicine of treatment chronic viral hepatitis B

(1) technical field: the invention belongs to medical product, be specifically related to-kind the treatment chronic viral hepatitis B medicine.

(2) background technology: chronic viral hepatitis B (hereinafter to be referred as " hepatitis B ") is a kind of common, pilosity, healthy infectious disease of serious harm people, nineteen eighty-three, World Health Organization (WHO) spelt out, and 80% liver cancer patient is all caused by hepatitis B virus; There are every year nearly 2,000,000 hepatitis B virus carrierss to die from liver cirrhosis or the hepatocarcinoma that causes by hepatitis B.At present, interferon is used to the treatment of hepatitis B at home as internationally recognized antiviral drugs.But because the difference of foreigner and Chinese's ethnic group, the viral gene type is also variant, and the sensitivity of interferon is differed, and therefore, total effective rate only about 30%, and relapse rate height after the drug withdrawal are as pre-C mutation, leukopenia etc.In addition, lamivudine, extrasin alpha ₁Also be used for the treatment of hepatitis B clinically; The former general medication after 1 year the HBV-DNA negative conversion rate can reach 80%, but HBeAg negative conversion rate 20-30% only, in case and after the drug withdrawal, promptly have a rebound; And latter's unsatisfactory curative effect; The common ground of said medicine is to cost an arm and a leg, one the course of treatment expense up to ten thousand yuan of 3-5, general patient is difficult to bear.

It is raw material with the natural Chinese medicinal herb that purpose of the present invention proposes a kind of exactly, according to the pathogeny of hepatitis B, and a kind of medicine for the treatment of hepatitis B that the utilization Traditional Chinese medical theory is carried out compatibility and preparation.

(3) summary of the invention: medicine of the present invention is made (consumption is a weight portion) by following component

Radix Astragali 20-50 Radix Angelicae Sinensis 20-50 Herba Rabdosiae Lophanthoidis 20-50

Formica fusca powder 20-50 Ganoderma spore powder 20-50 Carapax Et Plastrum Testudinis 20-50

Herba Artemisiae Scopariae 15-50 Radix Pseudostellariae 10-50 Radix Codonopsis 10-50

Rhizoma Atractylodis Macrocephalae 10-50 Placenta Hominis 50-100 Radix Bupleuri 10-20

Rhizoma Atractylodis 10-20 Herba Agrimoniae 10-20 Radix Cynanchi Paniculati 10-20

Nidus Vespae 10-20 Radix Et Rhizoma Rhei 10-20 Radix Morindae Officinalis 10-20

The short foot tea of Herba Abri 10-20 10-20 Herba Sedi 10-20

Herba Hedyotidis Diffusae 10-20 Zhu Cen 10-20 Radix Sophorae Tonkinensis 10-20

Rhizoma Polygoni Cuspidati 10-20 YUNCEN 10-20 Radix Paeoniae Rubra 10-20

Radix Salviae Miltiorrhizae 15-20 Eupolyphaga Seu Steleophaga 10-20 RHIZOMA BISTORTAE 10-20

Cacumen Securinegae Suffruticosae 10-20 Radix Polygoni Multiflori Preparata 10-20 Rhizoma Cimicifugae 10-20

Fructus Lycii 10-20 Radix Sophorae Flavescentis 10-20 Fructus Ligustri Lucidi 10-20

Radix Isatidis 10-20 Rhizoma Curcumae Longae 10-20 Endothelium corneum 10-20

Radix Glycyrrhizae 10-20

To be ground into 120 order fine powders after above-mentioned each component drying, can be prepared into oral formulations such as capsule, pill, powder, tablet respectively by the method on the pharmaceutics as required.

Clinical drug of the present invention uses the result to show that following advantage is arranged:

1. be prepared from by the pure natural Chinese herbal medicine, have effects such as heat-clearing and toxic substances removing, invigorating the spleen and benefiting QI, nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling; After taking medicine, the poison resistance that can enhancing body gets rid of illness improves liver function, removes virus, suppresses virus replication.

2. stable curative effect, it is little that poison is paid effect, low price.

3. applied widely, this medicine all has more definite curative effect to acute and chronic hepatitis B, HBsAg carrier, fatty liver, alcoholic liver, liver cirrhosis patient.

For further specifying curative effect of the present invention, we carry out random packet (these patients all are the patients that make a definite diagnosis by the hepatitis diagnostic criteria of whole nation viral hepatitis meeting revision in May nineteen ninety) to 240 routine patients, 120 people are organized in treatment, wherein male 74 examples, woman's 46 examples, age 7-56 year, course of disease 1-12, clinical serves as main performance, wherein abnormal liver function person 46 examples with poor appetite, weak, abdominal distention, pain in the right hypochondrium, pale tongue, thin fur or thick in vain, stringy and thready pulse or stringy and rolling pulse.Matched group 120 examples, male 82 examples, women 38 examples, age 8-56 year, course of disease 2-14, clinical manifestation is with the treatment group, wherein abnormal liver function person 38 examples.

The treatment group is taken the prepared capsule of medicine of the present invention, every g, and each 5, every day 3 times, per 3 months is a course of treatment; Matched group is taken " YIGANNING " electuary, each 1 bag, and every day 3 times, per 3 months is a course of treatment; Detect HBV mark and HBV-DNA when finish each course of treatment.

Criterion of therapeutical effect:

Cure in the recent period: clinical symptom disappearance, liver function recovery is normal; HBsAg turns out cloudy, and HBeAg turns out cloudy, and HBV-DNA turns out cloudy;

Produce effects: subjective symptoms disappears, and liver function recovery is normal, and HBeAg turns out cloudy, and HBV-DNA turns out cloudy;

Effectively: subjective symptoms disappears substantially, and liver function recovery is normal, but HBV mark and HBV-DNA no change;

Invalid: symptom and every index do not have significant change before and after the treatment.

Therapeutic outcome is as follows:

Group	The treatment group		Matched group
					Curative effect	Example	????％	Example	????％
Cure in the recent period	????32	????27	????13	????11
					Produce effects	????67	????56	????34	????29
Effectively	????14	????12	????54	????45
					Invalid	????7	????6	????19	????15
Total effective rate	????????94		????????85
					???????????????????????????P＜0.01

Treatment group serum HBsAg 32 examples (27%) of turning out cloudy, HBeAg 97 examples (81%) of turning out cloudy.Matched group serum HBSAg 13 examples (11%) of turning out cloudy, HBeAg 47 examples (39) of turning out cloudy.Two groups of property of comparing that there were significant differences.

The treatment group is cured in the recent period 32 examples, follows up a case by regular visits to 1 year, has 14 routine HBSAg to transfer the positive again to, but HBeAg and liver function no change turn out cloudy again after taking medicine once more, and produce effects 67 examples were followed up a case by regular visits to 1 year, and serum HBV mark and liver function there is no significant change.

(4) specific embodiment:

Take by weighing raw material (kilogram) by following proportioning:

The Radix Astragali 30 Radix Angelicae Sinensis 30 Herba Rabdosiae Lophanthoidiss 30

Formica fusca powder 30 Ganoderma spore powders 30 Carapax Et Plastrum Testudiniss 30

Herba Artemisiae Scopariae 30 Radix Pseudostellariaes 30 Radix Codonopsis 30

The Rhizoma Atractylodis Macrocephalae 30 Placenta Hominiss 80 Radix Bupleuri 15

Rhizoma Atractylodis 15 Herba Agrimoniaes 15 Radix Cynanchi Paniculatis 15

Nidus Vespae 15 Radix Et Rhizoma Rhei 15 Radix Morindae Officinaliss 15

Herba Abri 15 short foot tea 15 Herba Sedis 15

Herba Hedyotidis Diffusae 15 Zhu Cen 15 Radix Sophorae Tonkinensis 15

Rhizoma Polygoni Cuspidati 15 YUNCEN 15 Radix Paeoniae Rubra 15

Radix Salviae Miltiorrhizae 15 Eupolyphaga Seu Steleophagas 15 RHIZOMA BISTORTAEs 15

Cacumen Securinegae Suffruticosae 15 Radix Polygoni Multiflori Preparata 15 Rhizoma Cimicifugaes 15

Fructus Lycii 15 Radix Sophorae Flavescentiss 15 Fructus Ligustri Lucidi 15

Radix Isatidis 15 Rhizoma Curcumae Longaes 15 Endothelium corneum 15

Radix Glycyrrhizae 15

Above-mentioned raw materials is ground into 120 orders, sieves, the capsule of packing into No. 0, promptly.

Claims (2)

1. medicine for the treatment of chronic viral hepatitis B is characterized in that it is the medicament of being made by the following weight proportion raw material:

Radix Astragali 20-50 Radix Angelicae Sinensis 20-50 Herba Rabdosiae Lophanthoidis 20-50

Formica fusca powder 20-50 Ganoderma spore powder 20-50 Carapax Et Plastrum Testudinis 20-50

Herba Artemisiae Scopariae 15-50 Radix Pseudostellariae 10-50 Radix Codonopsis 10-50

Rhizoma Atractylodis Macrocephalae 10-50 Placenta Hominis 50-100 Radix Bupleuri 10-20

Rhizoma Atractylodis 10-20 Herba Agrimoniae 10-20 Radix Cynanchi Paniculati 10-20

Nidus Vespae 10-20 Radix Et Rhizoma Rhei 10-20 Radix Morindae Officinalis 10-20

The short foot tea of Herba Abri 10-20 10-20 Herba Sedi 10-20

Herba Hedyotidis Diffusae 10-20 Zhu Cen 10-20 Radix Sophorae Tonkinensis 10-20

Rhizoma Polygoni Cuspidati 10-20 YUNCEN 10-20 Radix Paeoniae Rubra 10-20

Radix Salviae Miltiorrhizae 15-20 Eupolyphaga Seu Steleophaga 10-20 RHIZOMA BISTORTAE 10-20

Cacumen Securinegae Suffruticosae 10-20 Radix Polygoni Multiflori Preparata 10-20 Rhizoma Cimicifugae 10-20

Fructus Lycii 10-20 Radix Sophorae Flavescentis 10-20 Fructus Ligustri Lucidi 10-20

Radix Isatidis 10-20 Rhizoma Curcumae Longae 10-20 Endothelium corneum 10-20

Radix Glycyrrhizae 10-20

2. a kind of medicine for the treatment of chronic viral hepatitis B according to claim 1 is characterized in that said medicament is capsule, tablet, pill or powder.